Clinical laboratory最新文献

{"title":"A Study on the Differences in the Probability of Iron Deficiency Anemia and the Severity of Anemia among People with Different Blood Types.","authors":"Luhao Guan, Xiaoling Huang, Biao Yan, Zebo Mou, Jiang He","doi":"10.7754/Clin.Lab.2025.251049","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.251049","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to explore the potential association between the ABO blood group system and the incidence probability as well as severity of Iron Deficiency Anemia (IDA), so as to provide a scientific basis for the personalized prevention, diagnosis, and intervention strategies of IDA.</p><p><strong>Methods: </strong>Statistical analyses were performed using SPSS software, including descriptive statistics, chi-squared test, Tukey HSD, Dunnett T3 multiple comparisons, and binary logistic regression model. A p-value < 0.05 was considered statistically significant.</p><p><strong>Results: </strong>Regarding hemoglobin distribution, the hemoglobin levels of 1,009 patients showed an approximately normal distribution, with a mean of 71 g/L and a standard deviation of 18 g/L. The median hemoglobin level of patients with blood type O (about 65 g/L) was significantly lower than that of other blood types, and the data distribution was more concentrated. For the association between blood type and gender, the sample size of females was generally larger than that of males, but the chi-squared test showed no significant association between blood type and gender (p > 0.05). In terms of anemia severity comparison, multiple comparison analysis indicated a significant difference only between blood types A and O (p = 0.013). Binary logistic regression showed that the risks of severe anemia in patients with blood type O (OR = 1.831, p = 0.001) and type A (OR = 1.488, p = 0.024) were 1.831 and 1.488 times that of type AB, respectively, while no significant association was found between blood type B and severe anemia (p > 0.05).</p><p><strong>Conclusions: </strong>The ABO blood group is associated with the severity of IDA. Individuals with blood types O and A have a significantly higher risk of severe IDA than those with blood type AB. This study provides a theoretical basis for blood group-based personalized screening and intervention of IDA, but further studies are needed to clarify the specific mechanism by which blood type affects iron metabolism and to exclude the influence of confounding factors such as eating habits and genetic background.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"72 10","pages":"2269-2275"},"PeriodicalIF":0.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treponema pallidum Hemagglutination (TPHA) Positivity Rates in HIV-Infected and Non-HIV-Infected Cases.","authors":"Ayşe Inci, Nagehan D Sari, Aysel Karataş, Gamze Konyali, Buse Koç","doi":"10.7754/Clin.Lab.2025.251015","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.251015","url":null,"abstract":"<p><strong>Background: </strong>Syphilis is a common co-infection among patients with human immunodeficiency virus (HIV) infection. Monitoring its prevalence is essential for effective public health control and prevention strategies.</p><p><strong>Methods: </strong>This retrospective study evaluated Treponema pallidum hemagglutination (TPHA) test results of patients followed at the Istanbul Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, between January 2019 and December 2021. Demographic and laboratory characteristics of HIV-infected patients were also analyzed.</p><p><strong>Results: </strong>A total of 1,436 patients with available TPHA results were included in the study. TPHA positivity was detected in 22.3% of all cases. Among these, 353 patients (24.6%) were HIV-infected. The age distribution did not significantly differ between TPHA-negative and TPHA-positive subgroups (p > 0.05). However, the proportion of male patients was significantly higher in the TPHA-positive subgroup compared with the TPHA-negative subgroup (p < 0.05). Marital status distribution did not differ significantly between TPHA-negative and TPHA-positive groups (p > 0.05).</p><p><strong>Conclusions: </strong>Given the increasing coexistence of syphilis and HIV infections in recent years, it is essential that individuals diagnosed with one sexually transmitted disease (STD) be screened for the other. Raising awareness among healthcare professionals and educating patients about the coexistence and transmission of sexually transmitted infections remain crucial for effective disease control and prevention.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"72 10","pages":"2221-2225"},"PeriodicalIF":0.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Differential Diagnostic Nomogram for Mycoplasma pneumoniae and Bordetella pertussis in Pediatric Upper Respiratory Infections.","authors":"Yating Liu, Bo Han, Hao Zhang, Qingbao Wang, Boke Zhang, Jun Zhu","doi":"10.7754/Clin.Lab.2025.250836","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.250836","url":null,"abstract":"<p><strong>Background: </strong>Differentiating Mycoplasma pneumoniae (MP) from Bordetella pertussis (BP) infections in children at primary care hospitals is challenging due to similar symptoms and overlapping epidemic seasons. This study evaluated the use of C-reactive protein (CRP) levels and lymphocyte counts from a single blood test to quickly distinguish between MP and BP infections.</p><p><strong>Methods: </strong>The study included a derivation cohort (n = 301) and a validation cohort (n = 87). Logistic regression analyses identified predictors for differentiating MP and BP infections, leading to the development of a prognostic scoring model and nomogram. The model's effectiveness was assessed using the area under the receiver operating characteristic curve (AUC) and calibration analysis.</p><p><strong>Results: </strong>CRP and lymphocyte count were key factors in distinguishing MP from BP infections (p < 0.001). A straightforward scoring model was developed utilizing these predictors. The score was significantly lower in the BP group compared to the MP group (-0.36 ± 0.17 vs. 2.09 ± 0.13; p < 0.001). The model exhibited excellent dis-criminative capability (AUC = 0.866), surpassing the performance of the neutrophil-to-lymphocyte ratio (NLR) (AUC = 0.704), CRP (AUC = 0.783), lymphocyte count (AUC = 0.838), and neutrophil count (AUC = 0.593). These findings were also validated in a separate cohort. Subsequently, a nomogram was constructed for clinical application.</p><p><strong>Conclusions: </strong>The proposed predictive scoring model and nomogram, which incorporate CRP and lymphocyte count, offer an accessible and practical tool for differentiating between MP and BP infections in pediatric patients with respiratory tract infections in primary care outpatient settings.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"72 10","pages":"2119-2125"},"PeriodicalIF":0.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Indole-3-Propanoic Acid Alleviates Pulmonary Inflammation in a Mouse Model of Bronchial Asthma by Regulating PD-1/PD-L1.","authors":"Guobin Cui, Haixing Feng, Shiji Xiao","doi":"10.7754/Clin.Lab.2025.251102","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.251102","url":null,"abstract":"<p><strong>Background: </strong>Bronchial asthma is a prevalent chronic inflammatory disorder of the airways, with children representing a particularly vulnerable population. Early intervention is critical for the management of pediatric asthma. The pathogenesis of asthma is primarily characterized by a Th2-immune response that drives excessive secretion of inflammatory cytokines, leading to allergic airway inflammation. Emerging evidence indicates that gut microbiota-derived metabolites modulate immune cells and influence asthma development and progression. Among these metabolites, indole derivatives with immunomodulatory properties have attracted increasing interest; however, the role of specific indole compounds in asthma remains poorly defined. This study aimed to inves-tigate the effect of indole-3-propionic acid (IPA), a key microbiota-derived indole metabolite, on allergic airway inflammation in a juvenile murine model of asthma, and to elucidate the underlying immunological mechanisms, with a focus on regulatory T cells (Tregs) and the Programmed cell death protein 1 (PD-1)/Programmed cell death ligand 1 (PD-L1) pathway.</p><p><strong>Methods: </strong>An asthma model was established in young mice via sensitization and challenge with ovalbumin (OVA). We evaluated the impact of IPA on pulmonary inflammation, airway hyperresponsiveness, inflammatory cell infiltration, cytokine profiles, and OVA-specific immunoglobulins. In addition, we analyzed Treg populations and the expression of PD-1 and PD-L1 in lung tissues.</p><p><strong>Results: </strong>Our results demonstrated that OVA-induced asthmatic mice exhibited significantly enhanced airway reactivity and pronounced inflammatory cell infiltration in lung histology. Bronchoalveolar lavage fluid (BALF) analysis revealed elevated total leukocyte counts, predominantly eosinophils and neutrophils. Levels of Th2 cytokines (IL-4, IL-5, and IL-13) were markedly increased in BALF, while concentrations of the anti-inflammatory cytokine IL-10 were decreased. Serum levels of OVA-specific IgE and IgG1 were elevated, further confirming a Th2-skipped immune response. Furthermore, a significant reduction in Treg frequency was observed in the lung tissues of asthmatic mice, accompanied by upregulation of PD-1 and PD-L1. Treatment with IPA effectively mitigated airway inflammation and reversed these immunological alterations by restoring Treg levels and modulating PD-1/PD-L1 expression.</p><p><strong>Conclusions: </strong>In conclusion, our findings indicate that IPA alleviates allergic airway inflammation in asthmatic juvenile mice by promoting Treg recruitment and function, potentially through the PD-1/PD-L1 axis. This study highlights the therapeutic potential of targeting microbial metabolite-mediated immunoregulation and provides new insights into early prevention and treatment strategies for asthma.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"72 10","pages":"2276-2284"},"PeriodicalIF":0.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics, Co-Mutations, and Prognostic Factors of TP53 Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndrome.","authors":"Xiaoqin Xin, Yanhong Li, Xiaoyu Li","doi":"10.7754/Clin.Lab.2025.250835","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.250835","url":null,"abstract":"<p><strong>Background: </strong>TP53 mutations confer poor prognosis and heterogeneous clinical features in myeloid neoplasms, but distinguishing factors between AML and MDS and independent prognostic markers within this high-risk group remain unclear.</p><p><strong>Methods: </strong>This retrospective study evaluated 45 adult patients with TP53-mutated acute myeloid leukemia (AML; n = 22) or myelodysplastic syndromes (MDS; n = 23) treated at Ganzhou People's Hospital between 2018 and 2023. Clinical, laboratory, cytogenetic, and targeted next-generation sequencing data were collected at diagnosis. Sixteen genes frequently mutated in myeloid malignancies were assessed for co-mutation patterns. Progression-free survival (PFS) and overall survival (OS) were analyzed by Kaplan-Meier and Cox regression; variables with univariate p < 0.10 entered multivariate models.</p><p><strong>Results: </strong>MDS patients were older than AML patients (65.5 ± 9.0 vs. 56.0 ± 15.1 years; p = 0.013), and exhibited lower bone marrow blast percentages (5.6% vs. 49.5%; p < 0.001), while AML cases had higher peripheral WBC counts (8.6 × 10⁹ vs. 2.9 × 10⁹/L; p = 0.002). DNMT3A and TET2 co-mutations were most frequent (15.6% each); FLT3-ITD was enriched in AML (18.2% vs. 0%; p = 0.049). In multivariate analysis, allogeneic HSCT (HR = 0.08; p = 0.022), higher RBC count (HR = 0.39; p = 0.011), hemoglobin (HR = 0.98; p = 0.043), and albumin (HR = 0.91; p = 0.010) independently predicted superior PFS, whereas RUNX1 co-mutation (HR = 18.15; p = 0.028) and lower ALT (HR = 0.97; p = 0.018) were independently associated with OS.</p><p><strong>Conclusions: </strong>Distinct clinical and molecular features differentiate TP53-mutated AML from MDS. Allogeneic HSCT confers marked survival benefit, and RUNX1 co-mutation identifies an ultra-high-risk subset. Early trans-plant evaluation combined with comprehensive genomic profiling is recommended to guide personalized treatment in this high-risk population.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"72 10","pages":"2109-2117"},"PeriodicalIF":0.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antimicrobial Resistance and Virulence Profiles of Acinetobacter baumannii in Pediatric Healthcare-Associated Bacteremia.","authors":"Mohamed Mefreh, Maysaa E S Zaki, Mona Abdelaltif, Mona A E-H A El-Raouf, Ahmed H El-Nagdy, Nadia G Elrefaei, Sara G Eissa","doi":"10.7754/Clin.Lab.2025.250964","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.250964","url":null,"abstract":"<p><strong>Background: </strong>Several factors play a role in the pathogenesis of Acinetobacter baumannii (A. baumannii). This study aimed to determine the virulence genes of A. baumannii isolated from healthcare-associated bacteremia (HAB) in pediatric patients, as well as their biofilm-forming ability and resistance to carbapenem antibiotics.</p><p><strong>Methods: </strong>One hundred isolates of A. baumannii from healthcare-associated bacteremia in children, collected be-tween January 2024 and January 2025, were subjected to biochemical identification using the API 20NE system, and confirmation of A. baumannii was performed by PCR targeting the blaOXA-51-like gene. Biofilm formation determination was quantified using the standard microtiter plate assay with crystal violet staining. Antimicrobial susceptibility testing was conducted using the Kirby-Bauer disc diffusion method on Mueller-Hinton agar. Genetic studies using the polymerase chain reaction (PCR) were performed to detect virulence-associated genes, including bap, surA1, pld, csuE, ompA, kps, and iron acquisition genes (basD, entE, and tonB) [17-22]. Screening for carbapenemase genes (blaOXA-23, blaOXA-24/40, blaOXA-58, blaNDM) was also conducted.</p><p><strong>Results: </strong>A. baumannii was able to form strong biofilm in 20%, intermediate biofilm in 30%, and weak biofilm in 25% of the isolates. All A. baumannii isolates contained the bap and surA1 genes (100%), the pld gene (84%), and the basD gene (79%).</p><p><strong>Conclusions: </strong>The significant presence of bap and surA1 genes among all imipenem-resistant and biofilm-forming isolates highlights their central role in enhancing both virulence and antimicrobial resistance. Moreover, there are significant correlations between imipenem resistance, omp33-36, and blaOXA-40, emphasizing the combined contribution of altered membrane permeability and carbapenemase activity to resistance phenotypes. The association of biofilm formation with blaOXA-23 and basD genes further reflects a multifactorial resistance strategy.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"72 10","pages":"2195-2200"},"PeriodicalIF":0.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Outcomes of First-Line Rituximab in Immune Thrombotic Thrombocytopenic Purpura.","authors":"Jia Wang, Aosen Dong, Yuanyuan Shen, Yi Dong","doi":"10.7754/Clin.Lab.2025.250905","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.250905","url":null,"abstract":"<p><strong>Background: </strong>Immune thrombotic thrombocytopenic purpura (iTTP) is an acute and life-threatening rare disease. While plasma exchange (PEX) and steroids have improved patient survival, mortality and relapse rates remain high.</p><p><strong>Methods: </strong>We performed a retrospective analysis of newly diagnosed iTTP patients admitted to the Second Affiliated Hospital of Anhui Medical University from May 2009 to May 2025. The treatment group received first-line rituximab combined with PEX and steroids, while the control group received PEX and steroids alone. Primary efficacy endpoints included clinical remission rate and 3-month mortality. Secondary efficacy endpoints comprised relapse rate, number of PEX sessions, ADAMTS13 activity recovery rate, cellular immune function, and overall survival (OS). The primary safety outcomes were infusion-related reactions, allergic reactions, and infection rates.</p><p><strong>Results: </strong>The clinical remission rates were 91.7% vs. 40% (p = 0.037) in the treatment and control groups, respectively. The 3-month mortality rates were 8.3% vs. 46.7% (p = 0.043). Relapse rates were 9.1% vs. 62.5% (p = 0.041). The median number of PEX sessions was 10 vs. 18 (p = 0.049). ADAMTS13 activity recovery rates were 75% vs. 26.7% (p = 0.021). During rituximab treatment, B cells showed a progressive decline, reaching 0.8% (0% - 3.12%) after the fourth infusion. By the follow-up cutoff in August 2025, 75% of patients had normalized B-cell counts. No effects were observed on CD4+ T cells, CD8+ T cells, or immunoglobulin (IgG, IgA, IgM) levels. The 5-year OS rates were 70.7% vs. 26.7%. Median survival times were 54.1 months (95% CI: 36.791 - 71.369) vs. 39.9 months (95% CI: 8.11 - 71.69) (p = 0.007). No increased infection rates were recorded in the treatment group during hospitalization or follow-up.</p><p><strong>Conclusions: </strong>First-line rituximab treatment can reduce mortality and relapse rates in iTTP patients, improve sur-vival outcomes, and demonstrates good safety.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"72 10","pages":"2136-2142"},"PeriodicalIF":0.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149134815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unlocking Prognostic Potential: Serum Uric Acid and Prothrombin Time as Predictors of HCC Recurrence.","authors":"Yanping Xiao, Qing Lin, Kunrong Yang, Guangjian Su","doi":"10.7754/Clin.Lab.2025.251001","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.251001","url":null,"abstract":"<p><strong>Background: </strong>This study aims to explore the prognostic value of pre-treatment serum uric acid (UA) and prothrombin time (PT) levels on the risk of tumor recurrence in patients with hepatocellular carcinoma (HCC) after receiving comprehensive therapy.</p><p><strong>Methods: </strong>A total of 199 HCC patients who underwent combination therapy (including surgical resection, local ablation, interventional therapy, and systemic therapy) at Fujian Cancer Hospital from January 2020 to December 2022 were consecutively enrolled. Baseline clinical data and pre-treatment laboratory indicators were collected. The primary endpoint was recurrence-free survival (RFS), with a median follow-up time of 19 months. The optimal cutoff values for UA and PT of predicting recurrence were determined using receiver operating characteristic (ROC) curves. Independent risk factors affecting RFS were analyzed using the Cox proportional hazards regression model. The Kaplan-Meier method was used to plot survival curves to compare differences between groups and to construct nomograms. Spearman's correlation analysis was also conducted.</p><p><strong>Results: </strong>A total of 116 patients (58.3%) experienced recurrence. Multivariate Cox regression analysis showed that UA (HR = 1.486, 95% CI: 1.009 - 2.189, p = 0.045) and PT (HR = 1.510, 95% CI: 1.011 - 2.261, p = 0.046) were independent risk factors for HCC recurrence. Furthermore, based on optimal cutoff values determined by ROC curve analysis, Kaplan-Meier survival analysis confirmed that recurrence-free survival (RFS) was significantly lower in the low-UA group and short-PT group (p < 0.05). Correlation analysis indicated that UA and PT had no significant correlation with alpha-fetoprotein (AFP), a traditional tumor marker for HCC, with p > 0.05, suggesting that their prognostic information is independent of traditional tumor markers.</p><p><strong>Conclusions: </strong>Elevated pre-treatment serum uric acid (UA) levels and prolonged prothrombin time (PT) are independent predictive factors for recurrence after combined therapy in HCC patients. These two indicators, as routine and easily accessible clinical tests, are cost-effective and have significant potential for application in improving postoperative risk stratification, identifying high-risk patient groups, and guiding individualized follow-up strategies for HCC patients.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"72 10","pages":"2201-2210"},"PeriodicalIF":0.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Hemorrhagic Shock Due to Abdominal Hemorrhage in Hemophilia A: The Role of Laboratory Medicine in Multidisciplinary Team.","authors":"Shuang Lou, Fan Yu","doi":"10.7754/Clin.Lab.2025.250958","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2025.250958","url":null,"abstract":"<p><strong>Background: </strong>Spontaneous abdominal hemorrhage due to hemophilia A is one of the most lethal complications, progressing rapidly and potentially leading to hemorrhagic shock or death.</p><p><strong>Methods: </strong>We report a case of a 38-year-old male patient with hemophilia A who presented with massive spontaneous abdominal hemorrhage, leading to a large hematoma and severe hemorrhagic shock. Upon admission, the patient showed unstable vital signs and a significant decline in hemoglobin levels, indicating an extremely perilous condition that required immediate multidisciplinary collaborative intervention.</p><p><strong>Results: </strong>A multidisciplinary team was assembled, including specialists from emergency medicine, intensive care, hematology, cardiothoracic surgery, laboratory medicine, and radiology. The team quickly diagnosed active abdominal hemorrhage and performed successful catheter-directed arterial embolization. Despite ongoing hemoglobin decline after the procedure, the multidisciplinary team employed targeted laboratory monitoring and assessments to identify underlying causes and adjust coagulation factor replacement and transfusion strategies, effectively stabilizing hemoglobin levels. During recovery, the patient developed progressive jaundice, which was determined to be due to the absorption of the large hematoma, thus preventing unnecessary invasive procedures.</p><p><strong>Conclusions: </strong>This case underscores the importance of a multidisciplinary approach in managing complex critical conditions and highlights the vital role of laboratory medicine in accurate diagnosis, decision-making, and management of complications.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"72 10","pages":"2314-2319"},"PeriodicalIF":0.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of mRNA Vaccination on the Progression of Chronic Kidney Disease.","authors":"Turker Emre, Fatoş Mete","doi":"10.7754/Clin.Lab.2026.260204","DOIUrl":"https://doi.org/10.7754/Clin.Lab.2026.260204","url":null,"abstract":"<p><strong>Introduction: </strong>During the coronavirus disease 2019 (COVID-19) pandemic, messenger ribonucleic acid (mRNA) vaccines, developed using a novel technology distinct from conventional vaccines, were widely administered. Compared to classical vaccines, mRNA vaccines are known to induce more pronounced immune responses. This study aimed to investigate whether mRNA and inactivated COVID-19 vaccines accelerate the progression of chronic kidney disease (CKD).</p><p><strong>Methods: </strong>A total of 140 patients with chronic kidney disease who were followed at Bursa City Hospital were retrospectively analyzed. Serum creatinine levels and glomerular filtration rate (eGFR) values were recorded at three different time points: the pre-vaccination period (-24 months), the vaccination period, and the post-vaccination period (+24 months). Glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Due to the dependent nature of pre- and post-vaccination comparisons, the paired t-test was used for parametric data, and the Wilcoxon signed-rank test for nonparametric data. Furthermore, we applied a One-Way ANOVA with Bonferroni post-hoc correction for intergroup comparisons. A p-value of less than 0.05 was considered statistically significant.</p><p><strong>Results: </strong>When stratified by vaccine type, all three subgroups (BioNTech-only, ınactivated-only, and mixed vaccination) exhibited significant within-group declines in eGFR and elevations in serum creatinine (p < 0.001 for all). Importantly, inter-group comparison using post-hoc analysis revealed no statistically significant difference in the magnitude of renal function change (delta eGFR or delta creatinine) between the different vaccine types (p > 0.05).</p><p><strong>Conclusions: </strong>The findings of this five-year retrospective cohort study indicate that neither mRNA-based nor inactivated COVID-19 vaccines accelerate the progression of chronic kidney disease. These results support the renal safety of both vaccine types in patients with chronic kidney disease and may help reduce concerns about vaccination-related deterioration in kidney function in this vulnerable population.</p>","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"72 10","pages":"2293-2299"},"PeriodicalIF":0.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}